Breaking News, Trials & Filings

Valneva COVID Vax Meets Co-primary Endpoints in Phase III Trial

Inactivated, adjuvanted VLA2001 demonstrates superiority against AZD1222 in terms of neutralization antibodies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva SE achieved positive results from the Phase 3 trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.  The trial recruited a total of 4,012 participants 18 and older across 26 trial sites in the UK. The trial met its co-primary endpoints: VLA2001 demonstrated superiority against AZD1222 (AstraZeneca and the University of Oxford Covid vaccine), in terms of geometric mean titer for neutralization antibodies, (VLA2001 GMT 803.5 (95%), (AZD1222 GMT 576.6 (95%), ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters